IN2012DN00908A - - Google Patents

Info

Publication number
IN2012DN00908A
IN2012DN00908A IN908DEN2012A IN2012DN00908A IN 2012DN00908 A IN2012DN00908 A IN 2012DN00908A IN 908DEN2012 A IN908DEN2012 A IN 908DEN2012A IN 2012DN00908 A IN2012DN00908 A IN 2012DN00908A
Authority
IN
India
Prior art keywords
polypeptides
factor
modified factor
methods
relates
Prior art date
Application number
Inventor
Brooks Alan
Patel Chandra
Jiang Xiaoqiao
Gritzan Uwe
Apeler Heiner
Wangjun
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of IN2012DN00908A publication Critical patent/IN2012DN00908A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to modified Factor IX polypeptides such as Factor IX polypeptides with one or more amino acid substitutions. The invention also relates to methods of making modified Factor IX polypeptides, and methods of using modified Factor DC polypeptides, for example, to treat patients afflicted with hemophilia B.
IN908DEN2012 2009-07-31 2010-08-02 IN2012DN00908A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00908A true IN2012DN00908A (en) 2015-04-03

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
IN908DEN2012 IN2012DN00908A (en) 2009-07-31 2010-08-02

Country Status (21)

Country Link
US (1) US20120164130A1 (en)
EP (1) EP2461821A4 (en)
JP (1) JP2013500726A (en)
KR (1) KR20120060209A (en)
CN (1) CN102573890A (en)
AU (1) AU2010278721A1 (en)
BR (1) BR112012002072A2 (en)
CA (1) CA2769258A1 (en)
CL (1) CL2012000238A1 (en)
CR (1) CR20120052A (en)
CU (3) CU20120018A7 (en)
DO (1) DOP2012000030A (en)
EA (1) EA201290069A1 (en)
EC (1) ECSP12011637A (en)
GT (1) GT201200023A (en)
IN (1) IN2012DN00908A (en)
MX (1) MX2012001346A (en)
PE (1) PE20121643A1 (en)
SG (1) SG178119A1 (en)
WO (1) WO2011014890A1 (en)
ZA (1) ZA201200716B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
EP4219547A3 (en) 2008-09-15 2023-10-18 uniQure biopharma B.V. Factor ix polypeptide mutant, its uses and a method for its production
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN102497884A (en) 2009-07-27 2012-06-13 巴克斯特国际公司 coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR101912335B1 (en) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 Glycopolysialylation of non-blood coagulation proteins
CN106110311A (en) 2009-07-27 2016-11-16 百深公司 Blood coagulation protein conjugates
DK2598172T3 (en) * 2010-07-30 2019-07-01 Baxalta GmbH Nucleophilic Catalysts for Oxygen Connection
HUE049352T2 (en) 2010-12-22 2020-09-28 Baxalta GmbH Materials and methods for conjugating a water soluble fatty acid derivative to a protein
CN104144950B (en) * 2011-12-19 2017-09-05 迪乐方有限责任公司 The glucosaminoglycan and its medical usage of non-anti-freezing containing the disaccharide unit repeated
BR112015011462A2 (en) * 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill Processes and Compositions for Modified Factor Ix Proteins
AU2014248617B2 (en) * 2013-03-13 2016-05-19 Ambrx, Inc. Modified canine leptin polypeptides
TW201519900A (en) * 2013-04-28 2015-06-01 Bayer Healthcare Llc Compositions and methods for inducing immune tolerance to coagulation factor proteins
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
BR112018002150A2 (en) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc factor ix fusion proteins and methods of manufacturing and using them
CA3034566A1 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
JP7578590B2 (en) 2018-10-18 2024-11-06 インテリア セラピューティクス，インコーポレーテッド Compositions and methods for expressing factor IX

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520259A (en) * 2001-04-25 2004-08-11 ���ݴ�ѧУ��ίԱ�� Method for hepatic gene transfer of factor 8/factor 9 by using spherical carrier to treat hemophilia
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
AU2010278721A1 (en) 2012-02-16
WO2011014890A1 (en) 2011-02-03
EP2461821A1 (en) 2012-06-13
CR20120052A (en) 2012-06-04
ZA201200716B (en) 2013-07-31
SG178119A1 (en) 2012-03-29
CN102573890A (en) 2012-07-11
PE20121643A1 (en) 2012-11-25
KR20120060209A (en) 2012-06-11
BR112012002072A2 (en) 2016-11-08
CU20130057A7 (en) 2013-06-28
CU20120018A7 (en) 2012-06-21
MX2012001346A (en) 2012-02-17
DOP2012000030A (en) 2012-02-29
CL2012000238A1 (en) 2012-10-05
CA2769258A1 (en) 2011-02-03
CU20130058A7 (en) 2013-06-28
ECSP12011637A (en) 2012-02-29
EP2461821A4 (en) 2013-07-03
JP2013500726A (en) 2013-01-10
EA201290069A1 (en) 2012-07-30
GT201200023A (en) 2014-01-27
US20120164130A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
IN2012DN00908A (en)
MX2011007930A (en) Crystalline insulin-conjugates.
MY192475A (en) Modified factor ix polypeptides and uses thereof
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
GEP20146056B (en) Acylated glucagon analogues
MX355543B (en) Peptidomimetic macrocycles.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
IN2012DN03883A (en)
IN2012DN02177A (en)
MX2012007438A (en) Oxyntomodulin peptide analogue.
JO3635B1 (en) Solid pharmaceutical compositions and processes for their production
MX2013009175A (en) Compositions comprising peroxy î±-ketocarboxylic acid and methods for producing and using the same.
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
MX2011014019A (en) Diazahomoadamantane derivatives and methods of use thereof.
EP2663576A2 (en) Novel wnt compositions and therapeutic uses of such compositions
MX349948B (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae.
MX356755B (en) Fumigillol type compounds and methods of making and using same.
MX2010010457A (en) Recombinant rhinovirus vectors.
MX359181B (en) Collagen hydrolysate and use thereof.
MX2012013875A (en) Peripheral blood sparc antibodies and uses thereof.
PH12014501200B1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2011008179A (en) Peptides for vaccine.